Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Jennifer C KeenanArielle J MedfordCharles S DaiSeth A WanderLaura M SpringAditya Bardia
Published in: Expert review of anticancer therapy (2024)
to gauge a tumor's endocrine sensitivity. Ongoing therapeutic and correlative biomarker studies will offer new insight and expanding treatment options for patients with advanced breast cancer.